Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · TAMPA, FL · NPI 1609189240
Verified facts
CMS Open Payments records show Marcus Matthew Janicki, D.O. received $27.45 in general payments during 2025 across 1 reported records.
Cipher Pharmaceuticals US LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $27.45 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $27.45 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $27.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 72 |
| Eliquis | Apixaban | 259 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 51 |
| Potassium Chloride | Potassium Chloride | 213 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 35 |
| Trazodone Hcl | Trazodone Hcl | 150 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 37 |
| Furosemide | Furosemide | 135 | 35 |
| Mirtazapine | Mirtazapine | 129 | 34 |
| Gabapentin | Gabapentin | 125 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 26 |
| Losartan Potassium | Losartan Potassium | 103 | 31 |
| Lisinopril | Lisinopril | 99 | 28 |
| Metformin Hcl | Metformin Hcl | 86 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 13 |
| Sertraline Hcl | Sertraline Hcl | 78 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 26 |
| Donepezil Hcl | Donepezil Hcl | 76 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Buspirone Hcl | Buspirone Hcl | 75 | 16 |
| Omeprazole | Omeprazole | 73 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 70 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 11 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 61 | suppressed |
| Levetiracetam | Levetiracetam | 58 | 16 |
| Sucralfate | Sucralfate | 57 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 11 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Carvedilol | Carvedilol | 52 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 16 |
| Memantine Hcl | Memantine Hcl | 52 | 11 |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Montelukast Sodium | Montelukast Sodium | 49 | 13 |
| Famotidine | Famotidine | 48 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Baclofen | Baclofen | 42 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | 11 |
| Finasteride | Finasteride | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 11 |
| Lactulose | Lactulose | 31 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Dilantin | Phenytoin Sodium Extended | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | 11 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Cephalexin | Cephalexin | 21 | 11 |
| Allopurinol | Allopurinol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 18 |
| Cefdinir | Cefdinir | 20 | 12 |
| Levofloxacin | Levofloxacin | 20 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Permethrin | Permethrin | 18 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.45 · 1 records | Cipher Pharmaceuticals US LLC | Natroba, Spinosad | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error